The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index; none of the 68 sources its claims cite is checked for support yet.
Reversal of Phospholamban Inhibition of the Sarco(endo)plasmic Reticulum Ca2+-ATPase (SERCA) Using Short, Protein-interacting RNAs and Oligonucleotide Analogs
Open accessAbstract
The sarco(endo)plasmic reticulum Ca 2+ -ATPase (SERCA) and phospholamban (PLN) complex regulates heart relaxation through its removal of cytosolic Ca 2+ during diastole. Dysfunction of this complex has been related to many heart disorders and is therefore a key pharmacological target. There are currently no therapeutics that directly target either SERCA or PLN. It has been previously reported that single-stranded DNA binds PLN with strong affinity and relieves inhibition of SERCA in a length-dependent manner. In the current article, we demonstrate that RNAs and single-stranded oligonucleotide analogs, or xeno nucleic acids (XNAs), also bind PLN strongly ( K d <10 nm) and relieve inhibition of SERCA. Affinity for PLN is sequence-independent. Relief of PLN inhibition is length-dependent, allowing SERCA activity to be restored incrementally. The improved in vivo stability of XNAs offers more realistic pharmacological potential than DNA or RNA. We also found that microRNAs (miRNAs) 1 and 21 bind PLN strongly and relieve PLN inhibition of SERCA to a greater extent than a similar length random sequence RNA mixture. This may suggest that miR-1 and miR-21 have evolved to contain distinct sequence elements that are more effective at relieving PLN inhibition than random sequences.
Overview
CoChat Summary
TL;DR
Random-sequence RNAs and nuclease-resistant oligonucleotide analogs bind phospholamban (PLN) with low-nanomolar affinity and relieve PLN inhibition of SERCA in a length-dependent manner. miR-1 and miR-21 also bind PLN and fully restore SERCA basal activity, more effectively than a random 20-mer RNA mixture.
Key findings
- Random-sequence RNA oligonucleotides longer than 5 nt bound PLN with high affinity; the 20-mer library showed 9–19 nM binding affinity. RNA showed no measurable affinity for SERCA (Kd > 4 µM) and only weak affinity for actin, myosin, and troponin.
- RNA relieved PLN-mediated SERCA inhibition length-dependently; the 50-mer restored SERCA basal activity (no statistical difference from SERCA alone, p > 0.05), while all lengths other than 5-mer and 10-mer were statistically different from WT PLN (p < 0.05).
- Charged XNAs (PT DNA, L-DNA, 2′-O-methyl RNA) bound PLN with Kd < 4 nM, similar to ssDNA/RNA; neutral PNA and morpholinos showed no measurable affinity. PT DNA had higher potency than the corresponding ssDNA 20-mer (p < 0.05), whereas L-DNA and 2′-O-methyl RNA gave less relief; only ssDNA and PT DNA showed pKCa statistically different from WT PLN.
- miR-1 and miR-21 bound PLN tightly (Kd ∼40–60 nM, versus ∼10 nM for random sequence) and fully restored SERCA basal activity (pKCa not statistically different from SERCA alone), more efficiently than a similar-length random RNA mixture.
Methods
- Binding affinities were measured by affinity capillary electrophoresis (ACE) and fluorescence polarization (FP) using FAM-labeled random-sequence oligonucleotide libraries titrated with PLN; a competition assay used unlabeled 20-mer RNA.
- SERCA ATPase activity was measured with a coupled enzyme assay in DOPC:DOPE (4:1) lipid vesicles containing SERCA alone or SERCA plus recombinant PLN; XNAs were added and incubated 25 min before assay, and pKCa was estimated from Hill equation fits (n = 3 or n = 6 replicates).
- SERCA1a was purified from rabbit skeletal muscle; PLN was recombinant; oligonucleotides included random-sequence ssDNA, RNA, 2′-O-methyl RNA, PT DNA, L-DNA, PNA, morpholinos, and miR-1/miR-21.
Limitations
- Stated: only 20-mer XNAs were used because of limitations in oligonucleotide synthesis; since longer RNA lengths had more potent effects, longer XNA sequences were expected to have a greater impact on pKCa.
- Stated: XNAs are potential therapeutics only if a suitable carrier can be developed; ssDNA is not viable due to short in vivo lifetime, and off-target/pleiotropic effects of miRNAs and antisense oligonucleotides may prevent therapeutic progression.
- Evident from the text: the current study reports in vitro binding and reconstituted lipid-vesicle ATPase assays; no in vivo or cellular validation of XNA or miRNA effects on the SERCA-PLN complex is presented here.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 0 Not valid · 30 Not checked · 52 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Only the additions of the ssDNA and the PT DNA show a statistically different pK Ca when compared with WT PLN (Fig. 6).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, electrostatics are not the only important factor when considering relief of SERCA inhibition (Fig. 6).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The slope of the curve is 1.32 ± 0.07”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“XNAs, on the other hand, display similar binding properties and activity toward the SERCA-PLN complex”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“SERCA affinity for calcium is decreased upon the addition of PLN(Fig. 2).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
39 more claims
Create a free account to see all 82 claims and to verify the 68 references still open.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 22
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous work has shown that random sequence ssDNA can bind with high affinity to phospholamban resulting in increased SERCA activity in solution studies8, 20.”
From Cytoplasmic nucleic acid-based XNAs directly enhance live cardiac cell function by a Ca2+ cycling-independent mechanism via the sarcomere (2019) · cites this paper as [8]
Citations
Cites
Crystal structure of the nucleosome core particle at 2.8 Å resolution
Luger, K., Mäder, A. W., Richmond, R. K., Sargent, D. F., & Richmond, T. J. (1997) · Nature · doi:10.1038/38444 · Cited by 9,466
Cardiac excitation–contraction coupling
Bers, D. M. (2002) · Nature · doi:10.1038/415198a · Cited by 4,744
Heidenreich, P. A., Trogdon, J. G., Khavjou, O. A., Butler, J., Dracup, K., Ezekowitz, M. D., Finkelstein, E. A., Hong, Y., Johnston, S. C., Khera, A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820a55f5 · Cited by 3,208
Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis
Zhao, Y., Samal, E., & Srivastava, D. (2005) · Nature · doi:10.1038/nature03817 · Cited by 1,557
Dysregulation of Cardiogenesis, Cardiac Conduction, and Cell Cycle in Mice Lacking miRNA-1-2
Zhao, Y., Ransom, J. F., Li, A., Vedantham, V., von Drehle, M., Muth, A. N., Tsuchihashi, T., McManus, M. T., Schwartz, R. J., & Srivastava, D. (2007) · Cell · doi:10.1016/j.cell.2007.03.030 · Cited by 1,429
Calcium Cycling and Signaling in Cardiac Myocytes
Bers, D. M. (2008) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.113006.100455 · Cited by 1,302
MicroRNAs in Development and Disease
Sayed, D., & Abdellatif, M. (2011) · Physiological Reviews · doi:10.1152/physrev.00006.2010 · Cited by 1,078
Functional screening identifies miRNAs inducing cardiac regeneration
Eulalio, A., Mano, M., Ferro, M. D., Zentilin, L., Sinagra, G., Zacchigna, S., & Giacca, M. (2012) · Nature · doi:10.1038/nature11739 · Cited by 1,029
Jessup, M., Greenberg, B., Mancini, D., Cappola, T., Pauly, D. F., Jaski, B., Yaroshinsky, A., Zsebo, K. M., Dittrich, H., & Hajjar, R. J. (2011) · Circulation · doi:10.1161/circulationaha.111.022889 · Cited by 760
MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles
van Rooij, E., & Olson, E. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3864 · Cited by 624
Cited by
Mayourian, J., Ceholski, D. K., Gorski, P. A., Mathiyalagan, P., Murphy, J. F., Salazar, S. I., Stillitano, F., Hare, J. M., Sahoo, S., Hajjar, R. J., et al. (2018) · Circulation Research · doi:10.1161/circresaha.118.312420 · Cited by 168
Mayourian, J., Ceholski, D. K., Gonzalez, D. M., Cashman, T. J., Sahoo, S., Hajjar, R. J., & Costa, K. D. (2018) · Circulation Research · doi:10.1161/circresaha.117.311589 · Cited by 91
Stroik, D. R., Ceholski, D. K., Bidwell, P. A., Mleczko, J., Thanel, P. F., Kamdar, F. D., Autry, J. M., Cornea, R. L., & Thomas, D. D. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.11.147 · Cited by 29
Viskupičová, J., & Espinoza-Fonseca, M. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169200 · Cited by 23
Neuregulin‐1 attenuates right ventricular diastolic stiffness in experimental pulmonary hypertension
Adão, R., Mendes‐Ferreira, P., Maia-Rocha, C., Santos‐Ribeiro, D., Gonçalves‐Rodrigues, P., Vidal‐Meireles, A., Monteiro‐Pinto, C., Pimentel, L., Falcão‐Pires, I., Keulenaer, G. W. D., et al. (2018) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13043 · Cited by 22
Liu, Y., Baumgardt, S. L., Fang, J., Shi, Y., Qiao, S., Bosnjak, Z. J., Vasquez-Vivar, J. M., Xia, Z., Warltier, D. C., Kersten, J. R., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-03234-6 · Cited by 21
Non and Epigenetic Mechanisms in Regulation of Adaptive Thermogenesis in Skeletal Muscle
Sahu, B., Pani, S., Swalsingh, G., & Bal, N. C. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00517 · Cited by 13
Dowrick, J. M., Tran, K., Garrett, A. S., Anderson, A. J., Nielsen, P. M. F., Taberner, A. J., & Han, J. (2022) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00137.2022 · Cited by 10
Lnc’ing Ca2+, SERCA and cardiac disease
Vervliet, T., Robinson, E. L., & Roderick, H. L. (2018) · Cell Calcium · doi:10.1016/j.ceca.2018.05.005 · Cited by 10
Karanja, C. W., Yeboah, K. S., Ong, W. W. S., & Sintim, H. O. (2020) · RSC Chemical Biology · doi:10.1039/d0cb00187b · Cited by 10
Benkner, A., Rüdebusch, J., Nath, N., Hammer, E., Grube, K., Groß, S., Dhople, V. M., Eckstein, G., Meitinger, T., Kaderali, L., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15910 · Cited by 10
Weber, D. K., Reddy, U. V., Robia, S. L., & Veglia, G. (2024) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2024.184370 · Cited by 8
Self-citationAutry, J. M., Karim, C. B., Perumbakkam, S., Finno, C. J., McKenzie, E. C., Thomas, D. D., & Valberg, S. J. (2020) · Veterinary Sciences · doi:10.3390/vetsci7040178 · Cited by 5
Zhang, Z., Tian, H., Chen, X., Zhao, H., Du, W., Gao, H., Luo, J., & Zheng, H. (2021) · Biochemical Engineering Journal · doi:10.1016/j.bej.2021.108015 · Cited by 3
Non-Coding RNAs in the Cardiac Action Potential and Their Impact on Arrhythmogenic Cardiac Diseases
Lozano-Velasco, E., Aránega, A. E., & Franco, D. (2021) · Hearts · doi:10.3390/hearts2030026 · Cited by 3
Stroik, D. R., Ceholski, D. K., Mleczko, J., Thanel, P. F., Bidwell, P. A., Autry, J. M., Cornea, R. L., & Thomas, D. D. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/699975 · Cited by 3
Thompson, B. R., Soller, K. J., Vetter, A., Yang, J., Veglia, G., Bowser, M. T., & Metzger, J. M. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.02.016 · Cited by 2
Self-citationZhang, J.-Y., Wu, J., Li, S., & Gong, Y. (2016) · Europe PMC (PubMed Central) · doi:10.3969/j.issn.1673-4254.2017.04.03 · Cited by 1
Exploration of altered molecular pathways involved in pathophysiology of LMNA-cardiomyopathy
Rodríguez, B. M. (2018) · theses.fr (ABES) · doi:10.70675/4ae5ce5cz0a8dz44d7z9c3bzf990ea66223b
Mkhize, S. A. (2025) · University of the Witwatersrand, Johannesburg Institutional Repository on DSpace (University of the Witwatersrand, Johannesburg)
Metadata
- Authors
- Soller, K. J., Yang, J., Veglia, G., & Bowser, M. T.
- Affiliations
- University of Minnesota (US)
- Corresponding author
- Veglia, Gianluigi
- Bowser, Michael T.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 291
- Issue
- 41
- Pages
- 21510-21518
- ISSN
- 0021-9258 (ISSN-L)
- PMC
- PMC5076822
- OpenAlex
- W2518314263
- Cited by
- 20
- References
- 55
- Citations by year
- 2025: 2 · 2024: 1 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 4 · 2018: 5 · 2017: 1 · 2016: 1
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 1433 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Funders
- National Institutes of Health (GM063533, GM072701)
- American Heart Association (13PRE16950023)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Keywords
- phospholamban, SERCA, sarco/endoplasmic reticulum Ca2+-ATPase, RNA-protein interactions, XNA, oligonucleotide analogues, miR-1, miR-21, heart failure
- MeSH terms
- Phospholamban, Calcium-Binding Proteins, Humans, Oligonucleotides, MicroRNAs, Sarcoplasmic Reticulum Calcium-Transporting ATPases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-18, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-18 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.